[Lipid-lowering therapy in the elderly : Who profits from which target values?]

Area of Science:

• Cardiovascular Medicine
• Preventive Cardiology
• Lipid Metabolism

Background:

• Lowering low-density lipoprotein (LDL) cholesterol reduces cardiovascular and cerebrovascular events.
• Current recommendations lack guidance on the optimal duration of cholesterol-lowering therapy.
• Economic factors and limited therapeutic options have historically influenced treatment duration.

Purpose of the Study:

• To determine optimal LDL cholesterol target values for cardiovascular prevention across different age groups.
• To evaluate the impact of lifelong versus later-onset cholesterol lowering therapy.
• To inform guidelines on the duration and intensity of statin therapy.

Main Methods:

• Review of existing literature on cholesterol-lowering therapy and cardiovascular outcomes.
• Analysis of studies investigating LDL cholesterol levels for primary and secondary prevention.
• Examination of data on the effect of cholesterol lowering on atheromatous plaque volume and vascular events.

Main Results:

• Optimal LDL cholesterol for primary prevention is below 100 mg/dL, ideally achieved lifelong from adolescence.
• For individuals with existing atheromatous deposits or later onset of treatment, target LDL cholesterol levels should be below 70 mg/dL, potentially 50-60 mg/dL.
• Earlier initiation of cholesterol lowering provides sustained benefits for over a decade in preventing vascular disease.

Conclusions:

• Lifelong maintenance of LDL cholesterol below 100 mg/dL from childhood is optimal for cardiovascular prevention.
• Treatment targets should be individualized based on age, risk factors, and presence of existing cardiovascular disease.
• Increased efficacy of modern therapies and declining statin prices support more aggressive and earlier cholesterol management.